Tonghua Dongbao Pharmaceutical 관리

관리 기준 확인 3/4

Tonghua Dongbao Pharmaceutical CEO는 Sheng Leng Chun, May2020 에 임명되었습니다 의 임기는 4.5 년입니다. 는 CN¥ 19.91M 가치에 해당하는 회사 주식의 0.12% 직접 소유합니다. 19.91M. 경영진과 이사회의 평균 재임 기간은 각각 4.5 년과 4.5 년입니다.

주요 정보

Sheng Leng Chun

최고 경영자

CN¥3.7m

총 보상

CEO 급여 비율	n/a
CEO 임기	4.5yrs
CEO 소유권	0.1%
경영진 평균 재임 기간	4.5yrs
이사회 평균 재임 기간	4.5yrs

최근 관리 업데이트

Recent updates

Tonghua Dongbao Pharmaceutical (SHSE:600867) Has A Pretty Healthy Balance Sheet

Oct 22

Tonghua Dongbao Pharmaceutical Co., Ltd.'s (SHSE:600867) Earnings Haven't Escaped The Attention Of Investors

Sep 30

Some May Be Optimistic About Tonghua Dongbao Pharmaceutical's (SHSE:600867) Earnings

Sep 06

Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) Analysts Just Slashed This Year's Estimates

Sep 05

Calculating The Intrinsic Value Of Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867)

Aug 22

Tonghua Dongbao Pharmaceutical (SHSE:600867) Has A Rock Solid Balance Sheet

Jun 19

Improved Earnings Required Before Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) Shares Find Their Feet

May 23

CEO

Sheng Leng Chun (50 yo)

4.5yrs

테뉴어

CN¥3,728,800

보상

Mr. Chun Sheng Leng serves as a Director and General Manager since Mach 27, 2024 and served as the Chairman and General Manager at Tonghua Dongbao Pharmaceutical Co., Ltd. since May 7, 2020 until March 27,...

리더십 팀

이름	위치	테뉴어	보상	소유권
Sheng Leng Chun	GM & Director	4.5yrs	CN¥3.73m	0.12% CN¥ 19.9m
Junyu Chi	Chief Accountant	4.5yrs	CN¥852.40k	데이터 없음
Hong Chen	Chief Engineer & Deputy GM	10.7yrs	CN¥527.20k	0.015% CN¥ 2.5m
Guodong Zhang	Deputy GM & Director	4.5yrs	CN¥1.17m	0.014% CN¥ 2.3m
Wenhai Zhang	Deputy GM & Director	4.5yrs	CN¥1.17m	0.031% CN¥ 5.2m
Zhiqiang Du	Deputy General Manager	3yrs	CN¥1.45m	데이터 없음
Fan Su	Deputy GM & Board Secretary	4.4yrs	CN¥992.50k	데이터 없음

4.5yrs

평균 재임 기간

50yo

평균 연령

경험이 풍부한 관리: 600867 의 관리팀은 경험 ( 4.5 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Sheng Leng Chun	GM & Director	10.7yrs	CN¥3.73m	0.12% CN¥ 19.9m
Guodong Zhang	Deputy GM & Director	4.5yrs	CN¥1.17m	0.014% CN¥ 2.3m
Wenhai Zhang	Deputy GM & Director	4.5yrs	CN¥1.17m	0.031% CN¥ 5.2m
Junye Wang	Chairman of the Supervisory Board	4.2yrs	CN¥1.17m	0.12% CN¥ 20.2m
Fu Bo Cao	Supervisor	4.5yrs	CN¥173.20k	데이터 없음
Wei Wang	Director	4.2yrs	데이터 없음	데이터 없음
Qingxia He	Employee Representative Supervisor	4.5yrs	데이터 없음	데이터 없음
Jiahong Li	Chairman of the Board	4.5yrs	CN¥173.20k	0.27% CN¥ 46.1m
Yan Bi	Independent Director	9.3yrs	CN¥100.00k	데이터 없음
Dai Xu	Independent Director	2.5yrs	CN¥100.00k	데이터 없음
Li Xu	Independent Director	2.5yrs	CN¥100.00k	데이터 없음
Jianchun Zhen	Director	1.2yrs	데이터 없음	데이터 없음

4.5yrs

평균 재임 기간

50yo

평균 연령

경험이 풍부한 이사회: 600867 의 이사회는 경험(평균 재직 기간 4.5 년)으로 간주됩니다.

Tonghua Dongbao Pharmaceutical 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Tonghua Dongbao Pharmaceutical Co., Ltd., Annual General Meeting, Apr 19, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Consensus EPS estimates fall by 57%, revenue upgraded

New minor risk - Earnings quality

Third quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Tonghua Dongbao Pharmaceutical (SHSE:600867) Has A Pretty Healthy Balance Sheet

Tonghua Dongbao Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Tonghua Dongbao Pharmaceutical Co., Ltd.'s (SHSE:600867) Earnings Haven't Escaped The Attention Of Investors

Investor sentiment improves as stock rises 16%

Some May Be Optimistic About Tonghua Dongbao Pharmaceutical's (SHSE:600867) Earnings

Consensus revenue estimates fall by 32%

Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) Analysts Just Slashed This Year's Estimates

Price target decreased by 9.8% to CN¥11.37

New minor risk - Earnings quality

New major risk - Dividend sustainability

Now 21% overvalued

Calculating The Intrinsic Value Of Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867)

Consensus EPS estimates fall by 11%

Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) announces an Equity Buyback for CNY 120 million worth of its shares.

Tonghua Dongbao Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Tonghua Dongbao Pharmaceutical (SHSE:600867) Has A Rock Solid Balance Sheet

Price target decreased by 8.4% to CN¥13.15

Improved Earnings Required Before Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) Shares Find Their Feet

Consensus EPS estimates increase by 14%

Consensus EPS estimates fall by 16%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Tonghua Dongbao Pharmaceutical Co., Ltd., Annual General Meeting, Apr 19, 2024

Investor sentiment improves as stock rises 16%

Full year 2023 earnings released: EPS: CN¥0.59 (vs CN¥0.79 in FY 2022)

Tonghua Dongbao Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 08, 2024

Price target increased by 7.4% to CN¥14.25

Price target increased by 8.2% to CN¥13.75

Adocia Announces its Partner Tonghua Dongbao Releases Positive Results on the Three Clinical Studies Conducted on BioChaperone Combo THDB0207 Formulation Containing Insulin Glargine and Insulin Lispro from Tonghua Dongbao

Consensus EPS estimates fall by 10%, revenue upgraded

Second quarter 2023 earnings: EPS misses analyst expectations

Tonghua Dongbao Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 22, 2023

Price target increased by 14% to CN¥12.83

Full year 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improves as stock rises 16%

Full year 2022 earnings released: EPS: CN¥0.80 (vs CN¥0.64 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to CN¥11.27

Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) commences an Equity Buyback for CNY 360 million worth of its shares, under the authorization approved on March 25, 2022.

Consensus forecasts updated

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates increase by 15%

Less than half of directors are independent

Full year 2021 earnings: EPS exceeds analyst expectations

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Full year 2021 earnings: EPS exceeds analyst expectations

An unknown buyer signed an agreement to acquire 5% stake in Xiamen Amoytop Biotech Co., Ltd. (SHSE:688278) from Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) for CNY 460 million.

Tonghua Dongbao Pharmaceutical Co., Ltd.(XSSC:600867) dropped from FTSE All-World Index (USD)

Third quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.10 in 3Q 2020)

Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) commences an Equity Buyback Plan for 24,000,000 shares, representing 1.18% for CNY 360 million, under the authorization approved on August 25, 2021.

Price target decreased to CN¥13.56

Second quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.13 in 2Q 2020)

Full year 2020 earnings released: EPS CN¥0.46 (vs CN¥0.40 in FY 2019)

Price target decreased to CN¥14.96

New 90-day low: CN¥11.82

Full year 2020 earnings released: EPS CN¥0.46

Revenue behind estimates

New 90-day low: CN¥12.87

New 90-day low: CN¥13.32

New 90-day high: CN¥14.91

Third quarter earnings released

Third-quarter earnings released: Revenue and earnings miss expectations

Earnings released

Tonghua Dongbao Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 20, 2020

CEO

테뉴어